IRIS Accounts Production v24.1.9.2 08015271 director 1.4.23 31.3.24 31.3.24 false true false false true false Ordinary A 1.00000 Ordinary B 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh080152712023-03-31080152712024-03-31080152712023-04-012024-03-31080152712022-03-31080152712022-04-012023-03-31080152712023-03-3108015271ns15:EnglandWales2023-04-012024-03-3108015271ns14:PoundSterling2023-04-012024-03-3108015271ns10:Director12023-04-012024-03-3108015271ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3108015271ns10:SmallEntities2023-04-012024-03-3108015271ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3108015271ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3108015271ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3108015271ns10:FullAccounts2023-04-012024-03-3108015271ns10:OrdinaryShareClass22023-04-012024-03-3108015271ns10:OrdinaryShareClass32023-04-012024-03-3108015271ns10:RegisteredOffice2023-04-012024-03-3108015271ns5:CurrentFinancialInstruments2024-03-3108015271ns5:CurrentFinancialInstruments2023-03-3108015271ns5:ShareCapital2024-03-3108015271ns5:ShareCapital2023-03-3108015271ns5:RetainedEarningsAccumulatedLosses2024-03-3108015271ns5:RetainedEarningsAccumulatedLosses2023-03-3108015271ns5:PlantMachinery2023-03-3108015271ns5:MotorVehicles2023-03-3108015271ns5:ComputerEquipment2023-03-3108015271ns5:PlantMachinery2023-04-012024-03-3108015271ns5:MotorVehicles2023-04-012024-03-3108015271ns5:ComputerEquipment2023-04-012024-03-3108015271ns5:PlantMachinery2024-03-3108015271ns5:MotorVehicles2024-03-3108015271ns5:ComputerEquipment2024-03-3108015271ns5:PlantMachinery2023-03-3108015271ns5:MotorVehicles2023-03-3108015271ns5:ComputerEquipment2023-03-3108015271ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3108015271ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3108015271ns5:DeferredTaxation2023-03-3108015271ns5:DeferredTaxation2024-03-3108015271ns10:OrdinaryShareClass22024-03-3108015271ns10:OrdinaryShareClass32024-03-31
REGISTERED NUMBER: 08015271 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 March 2024

for

BARE BIOLOGY LTD

BARE BIOLOGY LTD (REGISTERED NUMBER: 08015271)






Contents of the Financial Statements
for the year ended 31 March 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


BARE BIOLOGY LTD

Company Information
for the year ended 31 March 2024







DIRECTOR: M Lawson





REGISTERED OFFICE: Platform 9
Tower Point
44 North Road
Brighton
East Sussex
BN1 1YR





REGISTERED NUMBER: 08015271 (England and Wales)





ACCOUNTANTS: Plus Accounting
Chartered Accountants
Preston Park House
South Road
Brighton
East Sussex
BN1 6SB

BARE BIOLOGY LTD (REGISTERED NUMBER: 08015271)

Balance Sheet
31 March 2024

2024 2023
Notes £    £   
FIXED ASSETS
Tangible assets 4 77,283 1,139

CURRENT ASSETS
Stocks 1,108,318 453,484
Debtors 5 276,258 188,613
Cash at bank 147,365 519,773
1,531,941 1,161,870
CREDITORS
Amounts falling due within one year 6 (698,962 ) (306,843 )
NET CURRENT ASSETS 832,979 855,027
TOTAL ASSETS LESS CURRENT
LIABILITIES

910,262

856,166

PROVISIONS FOR LIABILITIES 7 (19,321 ) (285 )
NET ASSETS 890,941 855,881

CAPITAL AND RESERVES
Called up share capital 8 2 2
Retained earnings 890,939 855,879
SHAREHOLDERS' FUNDS 890,941 855,881

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

BARE BIOLOGY LTD (REGISTERED NUMBER: 08015271)

Balance Sheet - continued
31 March 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 31 July 2024 and were signed by:





M Lawson - Director


BARE BIOLOGY LTD (REGISTERED NUMBER: 08015271)

Notes to the Financial Statements
for the year ended 31 March 2024

1. STATUTORY INFORMATION

Bare Biology Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Revenue is measured at the fair value of the consideration received or receivable net of VAT and trade discounts, and is recognised as follows:

Revenue from the retail sales of vitamins and supplements is recognised at the point of sale.

Tangible fixed assets
Tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended by management.

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Office equipment-straight line over 4 years
Motor vehicles-20% reducing balance
Computer equipment-straight line over 3 years

Impairment policy
At each balance sheet date, the company reviews the carrying amount of its assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss, if any.

Stocks
Stocks, which consist of completed units of vitamins and supplements and raw materials, are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments
Financial assets, liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


BARE BIOLOGY LTD (REGISTERED NUMBER: 08015271)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in the Income Statement when they fall due. Amounts not paid are shown in accruals as a liability on the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 10 (2023 - 8 ) .

4. TANGIBLE FIXED ASSETS
Office Motor Computer
equipment vehicles equipment Totals
£    £    £    £   
COST
At 1 April 2023 8,435 - 18,053 26,488
Additions - 92,900 4,444 97,344
At 31 March 2024 8,435 92,900 22,497 123,832
DEPRECIATION
At 1 April 2023 8,435 - 16,914 25,349
Charge for year - 18,580 2,620 21,200
At 31 March 2024 8,435 18,580 19,534 46,549
NET BOOK VALUE
At 31 March 2024 - 74,320 2,963 77,283
At 31 March 2023 - - 1,139 1,139

BARE BIOLOGY LTD (REGISTERED NUMBER: 08015271)

Notes to the Financial Statements - continued
for the year ended 31 March 2024

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 183,777 143,178
Other debtors 92,481 45,435
276,258 188,613

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 200,482 40,989
Taxation and social security 293,057 206,857
Other creditors 205,423 58,997
698,962 306,843

7. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Deferred tax 19,321 285

Deferred
tax
£   
Balance at 1 April 2023 285
Accelerated capital allowances 19,036
Balance at 31 March 2024 19,321

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
1 Ordinary A £1 1 1
1 Ordinary B £1 1 1
2 2